SDC, Table S1. Overall imaging frequency variation per year post-LT in "Standard" and "High" risk patients. Complete protocol received from 27 and 21 transplant centers, respectively.


Post–LT Year	Frequency of Abdominal No. of Imaging Centers		%
	Standard Surveillance Protoco		
Year 1	Q3 month 11		40.74
- Tour T	Q4 month	2	7.41
	Q6 month	8	29.63
	Q12 month	4	14.81
Year 2	Q3 month	4	14.81
	Q6 month	11	40.74
	Q12 month	9	33.33
	Discontinued by 2 nd Yr	6	22.22
Year 3	Q3 month	1	3.7
	Q6 month	9	33.33
	Q12 month	8	29.63
	Discontinued by 3 rd Yr	3	11.11
>3 Years	Q3 month	0	0
	Q6 month	6	22.22
	Q12 month 9		33.33
	Discontinued by 5 th Yr	13	48.15
	"High-risk" Surveillance Protoc	col (n = 21)	
Year 1	Q3 month	15	71.43
	Q4 month	1	4.76
	Q6 month	7	33.33
	Q12 month	0	0
Year 2	Q3 month	10	47.62
	Q6 month	10	47.62
	Q12 month	1	4.76
	Discontinued by 2 nd Yr	3	14.28
Year 3	Q3 month	7	33.33
	Q6 month	10	47.62
	Q12 month	1	4.76
	Discontinued by 3 rd Yr	4	19.05
Year 4	Q3 month	7	33.33
	Q6 month	4	19.05
	Q12 month	3	14.28
	Discontinued by 4 th Yr	0	0
Year ≥ 5	Q3 month	7	33.33
	Q6 month	4	19.05
	Q12 month	3	14.28
	Discontinued by 5 th Yr	5	23.81

SUPPLEMENTAL FIGURE LEGENDS


SDC, Figure S1. Flow diagram describing survey responses.

SDC, Figure S2. Heat map of transplant center participation (based on US OPTN defined donor service areas).

SDC, Figure S1




SDC, Figure S2



Post-Liver Transplant (LT) Hepatocellular carcinoma (HCC) Recurrence Surveillance Protocol

Research study to identify spectrum of screening protocols for recurrence of HCC after LT

 $1. \ Please mention the UNOS (United Network for Organ Sharing) region of your$



Transplant Program.

2. Name of the Transplant Center/Institute including affiliations (under confidentiality)

) Willprovide(incommentfieldbelow)

Name

3. Your role:

Medical Director Transplant Hepatologist

Surgical Director

Other (please specify if completing on behalf of Medical Director)

4. How many adult liver transplants (range) are performed at your institution annually?

Post-Liver Transplant (LT) Hepatocellular carcinoma (HCC) I	Recurrence
SurveillanceProtocol	

Risk stratification

5. For patients transplanted due to HCC or found to have HCC on explant (incidental), does your center have a risk stratification method for recurrence post-LT?

◯ Yes	O No	
Other (please specify)		

Post-Liver Transplant (LT) Hepatocellular carcinoma (HCC) Recurrence Surveillance Protocol

Stratification criteria

6. If yes, then please list the risk categories patients are assigned to:

) "High"*vs*"Low"risk

"High" vs "Intermediate" vs "Low" Risk

7. Please list all the features used for "High" risk stratification at your center:

Explant Microvascularinvasion	AFP level: At transplant
Explant Outside imaging (MILAN/UCSF etc.) criteria	AFP level: Post-transplant (eg. downtrend or not)
 Explant Grade of differentiation AFP level:Pre-transplant 	Risk stratification "Models"
Other (please specify)	

8. If AFP levels used, then describe "cutoff" values used to define different risk categories (please include the timing of these values in relation to time of transplant eg. Pre, At or Post LT)?

9. If "Risk stratification Models" are used, please list the ones used at your program:

10. Do you have any surveillance protocol in practice for HCC patients post LT?

◯ Yes◯

No

Post-Liver Transplant (LT) Hepatocellular carcinoma (HCC) Recurrence Surveillance Protocol

Surveillance Protocols

11. If yes, please describe the protocol used for HCC surveillance post-LT at your

institution ("standard" protocol for all patients without risk stratification)

CT CT MRI Chest/Abdome	n/Pelvis MRI	AFP
est/Abdomen/PelvisAbdomen/Pelvis	Abdomen/Pelvis	
	 	\$
be the protocol (in detail):		
e the protocol (in detail):	\$	

12. Do you have any different (more intense) surveillance protocol for HCC in patients stratified as "high risk" for recurrence?

◯ Yes◯

No

Maybe

Post-Liver Transplant (LT) Hepatocellular carcinoma (HCC) Recurrence Surveillance Protocol


High Risk Protocol

13. Please describe the "High Risk" protocol used at your institution

(imaging/blood tests type and frequency):

	CT Abdomen	СТ	MRI Abdomen	MRI	AFP
		Chest/Abdomen/Pelvis		Chest/Abdomen/Pelvis	
Frequency	\$	\$	\$	\$	\$
Please desci	ribe the protoc	ol (in detail):			

14. In patients transplanted for HCC, is an effort made to use mTOR as part of the immunosuppression regimen when possible?



15. Would your institution be willing to participate in a study evaluating HCC screening/surveillance protocols and interested in sharing or contributing patient data?



Post-Liver Transplant (LT) Hepatocellular carcinoma (HCC) Recurrence Surveillance Protocol

Contact information

16. Please provide contact information (under confidentiality). If "yes" to previous question, you will be asked to estimate the number of HCC recurrence cases at your institution from the years 2014-2017.

Name		
Role		
(Med		
ical		
or		
Surgic		
al		
Direct		
or or		
"on		
behal		
f of")		
Institution		
State/Province	select state	▼ Email